 Amanda Wieland
Concepts (81)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Non-alcoholic Fatty Liver Disease | 6 | 2021 | 259 | 1.590 |
Why?
| | Hypertension, Portal | 1 | 2021 | 61 | 0.700 |
Why?
| | Liver Transplantation | 2 | 2018 | 814 | 0.700 |
Why?
| | Liver Diseases, Alcoholic | 1 | 2018 | 89 | 0.550 |
Why?
| | Hepatitis C | 1 | 2018 | 235 | 0.480 |
Why?
| | Dysbiosis | 1 | 2015 | 168 | 0.440 |
Why?
| | Diabetes Complications | 1 | 2015 | 228 | 0.410 |
Why?
| | Fatty Liver | 2 | 2024 | 232 | 0.400 |
Why?
| | Hepatitis C, Chronic | 3 | 2021 | 154 | 0.400 |
Why?
| | Intestines | 1 | 2015 | 347 | 0.390 |
Why?
| | Specialization | 1 | 2013 | 147 | 0.390 |
Why?
| | Physicians, Primary Care | 2 | 2018 | 233 | 0.380 |
Why?
| | Patient Education as Topic | 1 | 2015 | 739 | 0.330 |
Why?
| | Hepacivirus | 4 | 2021 | 235 | 0.330 |
Why?
| | Disease Management | 1 | 2013 | 597 | 0.320 |
Why?
| | Antiviral Agents | 3 | 2021 | 719 | 0.300 |
Why?
| | Microbiota | 1 | 2015 | 726 | 0.280 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1272 | 0.260 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1294 | 0.230 |
Why?
| | Obesity | 3 | 2024 | 2869 | 0.230 |
Why?
| | Elasticity Imaging Techniques | 1 | 2024 | 48 | 0.220 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2024 | 91 | 0.220 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2024 | 87 | 0.210 |
Why?
| | Colonic Polyps | 1 | 2024 | 87 | 0.200 |
Why?
| | Liver Cirrhosis | 2 | 2024 | 277 | 0.200 |
Why?
| | Colonoscopy | 1 | 2024 | 228 | 0.190 |
Why?
| | Artificial Intelligence | 1 | 2024 | 251 | 0.180 |
Why?
| | Simeprevir | 2 | 2017 | 8 | 0.180 |
Why?
| | Sofosbuvir | 2 | 2017 | 58 | 0.170 |
Why?
| | Interferons | 1 | 2021 | 193 | 0.170 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1854 | 0.160 |
Why?
| | T-Lymphocyte Subsets | 1 | 2021 | 412 | 0.160 |
Why?
| | Single-Cell Analysis | 1 | 2021 | 274 | 0.160 |
Why?
| | Waiting Lists | 1 | 2018 | 250 | 0.130 |
Why?
| | Protease Inhibitors | 1 | 2017 | 105 | 0.130 |
Why?
| | Drug Costs | 1 | 2017 | 111 | 0.130 |
Why?
| | Drug Interactions | 1 | 2017 | 370 | 0.120 |
Why?
| | Transcriptome | 1 | 2021 | 890 | 0.120 |
Why?
| | Humans | 13 | 2024 | 130305 | 0.120 |
Why?
| | Metagenome | 1 | 2015 | 137 | 0.120 |
Why?
| | Risk Factors | 4 | 2021 | 9865 | 0.110 |
Why?
| | Models, Animal | 1 | 2015 | 373 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2024 | 10341 | 0.100 |
Why?
| | Education, Medical, Continuing | 1 | 2013 | 123 | 0.100 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 2549 | 0.100 |
Why?
| | Prevalence | 2 | 2021 | 2576 | 0.090 |
Why?
| | Surveys and Questionnaires | 2 | 2015 | 5400 | 0.090 |
Why?
| | Middle Aged | 6 | 2024 | 31322 | 0.090 |
Why?
| | Body Mass Index | 2 | 2021 | 2268 | 0.090 |
Why?
| | Female | 8 | 2024 | 68842 | 0.090 |
Why?
| | Data Collection | 1 | 2013 | 654 | 0.090 |
Why?
| | United States | 2 | 2018 | 14110 | 0.080 |
Why?
| | Male | 8 | 2024 | 63748 | 0.080 |
Why?
| | Adult | 5 | 2024 | 35711 | 0.080 |
Why?
| | Aged | 4 | 2024 | 22282 | 0.070 |
Why?
| | Insulin Resistance | 1 | 2015 | 1167 | 0.070 |
Why?
| | Drug Therapy, Combination | 2 | 2017 | 1028 | 0.060 |
Why?
| | Liver | 2 | 2024 | 1846 | 0.050 |
Why?
| | Adenoma | 1 | 2024 | 213 | 0.050 |
Why?
| | Prospective Studies | 2 | 2024 | 7131 | 0.040 |
Why?
| | Sustained Virologic Response | 1 | 2017 | 36 | 0.030 |
Why?
| | Models, Economic | 1 | 2017 | 59 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1029 | 0.030 |
Why?
| | Colorectal Neoplasms | 1 | 2024 | 733 | 0.030 |
Why?
| | Pharmacy | 1 | 2017 | 32 | 0.030 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2017 | 84 | 0.030 |
Why?
| | Remission Induction | 1 | 2017 | 270 | 0.030 |
Why?
| | Ribavirin | 1 | 2017 | 92 | 0.030 |
Why?
| | Life Style | 1 | 2018 | 461 | 0.030 |
Why?
| | Analgesics | 1 | 2017 | 165 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2024 | 1218 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1442 | 0.030 |
Why?
| | Pharmacists | 1 | 2017 | 263 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 621 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2024 | 14675 | 0.030 |
Why?
| | Weight Loss | 1 | 2018 | 728 | 0.030 |
Why?
| | Animals | 1 | 2015 | 35076 | 0.030 |
Why?
| | Genotype | 1 | 2017 | 1839 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 3923 | 0.020 |
Why?
| | Primary Health Care | 1 | 2018 | 1677 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4471 | 0.020 |
Why?
|
|
Wieland's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|